Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

316
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
316
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

352
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
352
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

201
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
201
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

141
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
141
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

79
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
79
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

243
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
243

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of anemia in patients with chronic kidney disease attended at a nephrology outpatient clinic and its association with the outcome of renal replacement therapy over five years: a retrospective cohort study, Municipality of São Paulo, 2010-2018.

Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil·2026
Same author

Exploring the retention of soluble Fas protein in kidney dysfunction and its link to inflammation: a systematic review and meta-analysis.

Jornal brasileiro de nefrologia·2026
Same author

Association between hemoglobin/red blood cell distribution width ratio and acute kidney injury in sepsis and heart failure patients.

PloS one·2026
Same author

Collapsing Glomerulopathy in Brazil: A Nationwide Descriptive Study.

Nephrology (Carlton, Vic.)·2025
Same author

Analysis of Auditory Function before and after a Single Session of Hemodialysis in Patients with Chronic Kidney Disease.

International archives of otorhinolaryngology·2025
Same author

Adenovirus Interstitial Nephritis After Kidney Transplant: Case Series and Literature Review.

Kidney360·2025

Related Experiment Video

Updated: Nov 16, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.1K

FGF21 and Chronic Kidney Disease.

João Victor Salgado1, Miguel Angelo Goes2, Natalino Salgado Filho3

  • 1Division of Nephrology, Federal University of São Paulo, Brazil; Department of Physiological Sciences, Federal University of Maranhão, Brazil.

Metabolism: Clinical and Experimental
|February 22, 2021
PubMed
Summary

Fibroblast growth factor 21 (FGF21) impacts lipid, glucose, and energy metabolism. This review explores FGF21

Keywords:
BoneCardiovascular diseaseDiabetes treatmentDialysis therapyNephropathyObesity

More Related Videos

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.2K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.0K

Related Experiment Videos

Last Updated: Nov 16, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.1K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.2K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.0K

Area of Science:

  • Endocrinology
  • Nephrology
  • Metabolic Research

Background:

  • Chronic kidney disease (CKD) presents a growing global health challenge.
  • Early diagnosis and novel therapeutics are crucial for managing CKD progression and complications.
  • Fibroblast growth factor 21 (FGF21) is a key regulator of metabolic homeostasis and stress responses.

Purpose of the Study:

  • To review the biological effects of FGF21.
  • To summarize current knowledge on FGF21's role in chronic kidney disease (CKD).
  • To identify research gaps regarding FGF21's function in the kidney.

Main Methods:

  • Literature review of studies on FGF21 and renal function.
  • Analysis of existing data on FGF21's association with metabolic and kidney diseases.
  • Synthesis of information on FGF21's biological actions.

Main Results:

  • FGF21 analogs show promise in metabolic disease models and patients.
  • Over a decade of research links FGF21 to renal function.
  • The precise functional role of FGF21 within the kidney remains largely unclear.

Conclusions:

  • FGF21 is a significant metabolic regulator with potential implications for kidney health.
  • Further research is essential to elucidate FGF21's specific functions in the kidney and its therapeutic potential in CKD.
  • Understanding FGF21's role could lead to new strategies for managing chronic kidney disease.